184 related articles for article (PubMed ID: 30150180)
1. In vitro efficacy of linezolid against vancomycin resistant Enterococci.
Hussain MS; Sattar A; Hussain M
Pak J Pharm Sci; 2018 Sep; 31(5):1853-1857. PubMed ID: 30150180
[TBL] [Abstract][Full Text] [Related]
2. Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.
Klupp EM; Both A; Belmar Campos C; Büttner H; König C; Christopeit M; Christner M; Aepfelbacher M; Rohde H
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1957-1961. PubMed ID: 27525679
[TBL] [Abstract][Full Text] [Related]
3. Linezolid activity against clinical Gram-positive cocci with advanced antimicrobial drug resistance in Iran.
Houri H; Kazemian H; Sedigh Ebrahim-Saraie H; Taji A; Tayebi Z; Heidari H
J Glob Antimicrob Resist; 2017 Sep; 10():200-203. PubMed ID: 28735054
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis.
Melese A; Genet C; Andualem T
BMC Infect Dis; 2020 Feb; 20(1):124. PubMed ID: 32046668
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
6. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
7. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature.
Bender JK; Cattoir V; Hegstad K; Sadowy E; Coque TM; Westh H; Hammerum AM; Schaffer K; Burns K; Murchan S; Novais C; Freitas AR; Peixe L; Del Grosso M; Pantosti A; Werner G
Drug Resist Updat; 2018 Sep; 40():25-39. PubMed ID: 30447411
[TBL] [Abstract][Full Text] [Related]
8. Validating a screening agar for linezolid-resistant enterococci.
Werner G; Fleige C; Klare I; Weber RE; Bender JK
BMC Infect Dis; 2019 Dec; 19(1):1078. PubMed ID: 31870418
[TBL] [Abstract][Full Text] [Related]
9. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.
Mohammad H; AbdelKhalek A; Abutaleb NS; Seleem MN
Int J Antimicrob Agents; 2018 Jun; 51(6):897-904. PubMed ID: 29432868
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
12. Detection of vancomycin resistance in enterococcus species isolated from clinical samples and feces of colonized patients by phenotypic and genotypic methods.
Biswas PP; Dey S; Adhikari L; Sen A
Indian J Pathol Microbiol; 2016; 59(2):188-93. PubMed ID: 27166038
[TBL] [Abstract][Full Text] [Related]
13. High rate of linezolid intermediate susceptibility and resistance among enteric vancomycin-resistant Enterococcus (VRE) recovered from hospitalized patients actively screened for VRE colonization.
Dilworth TJ; Beck ET; Pedersen RA; Al-Karkokly WG; Cook MM; Aldag EK; Kramer DJ; Sahajpal AK; Nadeem I; Buggy BP; Brummitt CF
Infect Control Hosp Epidemiol; 2019 Jul; 40(7):821-822. PubMed ID: 31088583
[No Abstract] [Full Text] [Related]
14. Species, antibiotic susceptibility profiles and van gene frequencies among enterococci isolated from patients at Mulago National Referral Hospital in Kampala, Uganda.
Kateete DP; Edolu M; Kigozi E; Kisukye J; Baluku H; Mwiine FN; Najjuka CF
BMC Infect Dis; 2019 May; 19(1):486. PubMed ID: 31151413
[TBL] [Abstract][Full Text] [Related]
15. First outbreak of linezolid-resistant vancomycin-resistant Enterococcus faecium in an Irish hospital, February to September 2014.
O'Driscoll C; Murphy V; Doyle O; Wrenn C; Flynn A; O'Flaherty N; Fenelon LE; Schaffer K; FitzGerald SF
J Hosp Infect; 2015 Dec; 91(4):367-70. PubMed ID: 26520594
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
17. Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.
AbdelKhalek A; Abutaleb NS; Elmagarmid KA; Seleem MN
Sci Rep; 2018 May; 8(1):8353. PubMed ID: 29844350
[TBL] [Abstract][Full Text] [Related]
18. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy.
Lellek H; Franke GC; Ruckert C; Wolters M; Wolschke C; Christner M; Büttner H; Alawi M; Kröger N; Rohde H
Int J Med Microbiol; 2015 Dec; 305(8):902-9. PubMed ID: 26454536
[TBL] [Abstract][Full Text] [Related]
19. Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium.
Smith TT; Tamma PD; Do TB; Dzintars KE; Zhao Y; Cosgrove SE; Avdic E
Diagn Microbiol Infect Dis; 2018 Jun; 91(2):161-163. PubMed ID: 29496381
[TBL] [Abstract][Full Text] [Related]
20. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
Papadimitriou-Olivgeris M; Kolonitsiou F; Zerva L; Lebessi E; Koutsia C; Drougka E; Sarrou S; Giormezis N; Vourli S; Doudoulakakis A; Konsolakis C; Marangos M; Anastassiou ED; Petinaki E; Spiliopoulou I
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):386-8. PubMed ID: 26341703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
